News
WuXi Vaccines’ First Drug Substance Facility in China Released for GMP Manufacturing
WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced the successful GMP release of its CHO cell-based drug substance (DS) manufacturing facility located in Suzhou, China.
Singapore’s Mirxes to List in Hong Kong After Securing $50M in Series D Funding
Mirxes Holding Company Limited, a Singapore-headquartered biotech firm, announced Tuesday that it has filed listing application with The Stock Exchange of Hong Kong Limited after securing $50 million Series D funding.
PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the first patient has been dosed in the Phase I clinical trial of PMC-403, the Company's novel TIE2 agonistic antibody, in nAMD (neovascular age-related macular degeneration).
Samsung Biologics Reports Second Quarter 2023 Financial Results
Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), today announced financial results for the second quarter of fiscal year 2023.
Dr. Reddy’s Q1 FY24 Financial Results
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2023.
Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today XERAVA® (eravacycline) has been successfully launched in China with its first prescription issued at Huashan Hospital affiliated to Fudan University.
LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis
Tarsus Pharmaceuticals (Tarsus) announced yesterday that the U.S. Food and Drug Administration (FDA) approved XDEMVY™ (lotlilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis.
Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its Aderamastat Phase 2 Study Results at the European Respiratory Society (ERS) International Congress 2023
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today that the company has been selected for a late-breaking oral presentation on the positive primary outcomes of its aderamastat (FP-025) Phase 2 proof-of-concept allergic asthma study at the European Respiratory Society (ERS) International Congress 2023 taking place in Milan, Italy from September 9-13, 2023.
Mabwell to Present Clinical Trial Data of 2 Programs at ESMO Congress 2023
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical trial data from phase I/II study for advanced solid tumor of Nectin-4-targeting ADC (9MW2821), and phase III study of Long-Acting Recombinant Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor (I) Fusion Protein (8MW0511) will be presented orally and as a poster respectively at ESMO Congress 2023.
InnoCare Announces Approval of Clinical Trial of pan-TRK Inhibitor Zurletrectinib for the Treatment of Pediatric Patients in China
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has received approval to conduct clinical trial of its second generation pan-TRK inhibitor zurletrectinib (ICP-723) to treat pediatric patients (2 to 12 years old) in China.
